ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Caixin

Chinese mRNA vaccine developer raises a record $200m

Fresh funds to finance clinical trials and production of vaccine candidate

Venture capital is continuing to pour into the novel technology to fight COVID-19 and future viral threats.   © Reuters

Vaccine startup Stemirna Therapeutics has raised $200 million -- a record for Chinese vaccine developers specializing in messenger RNA (mRNA) technology -- showing that venture capital continues to bet on the technology to combat the COVID-19 pandemic and future viral threats.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more